BridgeMD
Compares treatment options for Tracheal Intubation
Official title Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation
ClinicalTrials.gov ID: NCT06564857
What this study is testing
What is Remifentanil?
Remifentanil is an investigational medicine, being studied as a potential treatment for tracheal intubation.
Also referred to as Remifentanil 5 mg diluted in 100 ml saline, which corresponds to Remifentanil 50 micrograms/ml.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Globally, we are approaching 1 million surgical procedures each day. Tracheal intubation is the mainstay of securing the patient's airway and breathing during general anaesthesia.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults ≥ 18 years
- Undergoing general anaesthesia requiring oro-tracheal intubation
- Absence of indication for rapid sequence induction
- American Society of Anesthesiologists (ASA) physical status score I - III
You likely can't join if
- Known allergies or contraindications to rocuronium (e.g. neuromuscular disease) or remifentanil
- Awake intubation
- Double-lumen endotracheal tube
- Oral, pharyngeal, and laryngeal surgery
- Surgical contraindication for NMBAs (e.g. use of nerve stimulator)
- Patients who are pregnant or breastfeeding
See the full eligibility criteria
- Adults ≥ 18 years
- Undergoing general anaesthesia requiring oro-tracheal intubation
- Absence of indication for rapid sequence induction
- American Society of Anesthesiologists (ASA) physical status score I - III
- Known allergies or contraindications to rocuronium (e.g. neuromuscular disease) or remifentanil
- Awake intubation
- Double-lumen endotracheal tube
- Oral, pharyngeal, and laryngeal surgery
- Surgical contraindication for NMBAs (e.g. use of nerve stimulator)
- Patients who are pregnant or breastfeeding
- Patients who do not understand Danish or are unable to give informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Copenhagen, Denmark
- Hillerød, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Copenhagen, Denmark; Hillerød, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.